Exenatide antidiabetic drugs
systematic review meta-analysis network meta-analysis
 

AC 2993 - Byetta - AC 2993 LAR - exendin 4 - Ex4 peptide - exendin-4 - bydureon - exenatide      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultcardiovascular eventsAll cause death

diabetes type 2  

NCT00360334    NCTexenatideglarginenegative-2%
Derosa, 2010     exenatide 20µgglibenclamidenegative
Liutkus, 2010     exenatideplacebonegative
EXSCEL, 2017    NCTexenatideplaceboLow risk of bias conclusive-9%-14%
H8O-MC-GWBJ, 9698, 10µg/d, 2008   exenatide 10µg/dplaceboLow risk of bias -
Apovian, 2010     exenatide 20µg/dplaceboLow risk of bias negative
H8O-MC-GWBJ, 9698, 20µg/d, 2008   exenatide 20µg/dplaceboLow risk of bias -
Moretto (DOUBLONS avec druker), 2008      NCTexenatide other dosesplaceboLow risk of bias negative
NCT00085969    NCTexenatide other dosesplaceboLow risk of bias -
Poon, 2005        NCTexenatide other dosesplaceboLow risk of bias -
Buse, 2011      NCTexenatide 20µg/dplacebo (add on insulin)Low risk of bias negative -100%
Fineman, 2003     exenatide other dosesplacebo (add on MER+/-SU)Exploratory -
DeFronzo 10µg/d, 2005          NCTexenatide 10µg/dplacebo (add on MET)Low risk of bias negative
DeFronzo 20µg/d, 2005      NCTexenatide 20µg/dplacebo (add on MET)Low risk of bias suggesting
Kim, 2007      NCTexenatide weeklyplacebo (add on MET)Exploratory negative
Gao, 2009      NCTexenatide 20µg/dplacebo (add on MET+/-SU)Low risk of bias suggesting -100%
Buse 10µg/d, 2004          NCTexenatide 10µg/dplacebo (add on SU)negative
Buse 20µg/d, 2004     exenatide 20µg/dplacebo (add on SU) -
Kadowaki (trial 8683), 2009     exenatide 10µg/dplacebo (add on SU+/-MET/TZD)Exploratory negative
Kendall 10µg/d, 2005      NCTexenatide 10µg/dplacebo (add on SU+MET)Low risk of bias negative
Kendall 20µg/d, 2005      NCTexenatide 20µg/dplacebo (add on SU+MET)Low risk of bias suggesting -100%
Zinman 20µg/j, 2007    NCTexenatide 20µg/dplacebo (add on TZD+/-MET)Low risk of bias suggesting
Zinman 20µg/j A MODIFIER, 2007   exenatide 20µg/dplacebo (add on TZD+/-MET)Low risk of bias -
Gill, 2010     exenatide 10µg/dplacebo add on MET+/-TZDLow risk of bias negative
phase 2 exenatide once monthly   exenatide once monthlyweekly exenatide -
Bergenstal (once daily), 2009     exenatide 20µg/dBIAsp 30 dailyRisk of bias -
Bergenstal (twice daily), 2009     exenatide 20µg/dBIAsp 30 twice dailyRisk of bias negative
Exenatide Trial 10749   exenatide before lunch and dinnerexenatide before breakfast and dinnerRisk of bias -
HEELA (Davies), 2009   exenatide other dosesglargine -
Heine, 2005   exenatide 20µg/dinsulin (add on SU+MET)negative 58%
Davis, 2007      NCTexenatide 20µg/dinsulin (add on SU/MET)Risk of bias negative ∞%
Barnett, 2007      NCTexenatide 20µg/dinsulin (add on SU/MET)Exploratory suggesting
Nauck, 2007      NCTexenatide 20µg/dinsulin BIAsp twice daily add on SU+METRisk of bias negative 96%96%
DURATION-3 (Diamant), 2010    NCTexenatide weeklyinsulin glargineRisk of bias suggesting ∞%
Bunck, 2009          NCTexenatide 20µg/dinsulin glargine (add on MET)Exploratory -
Trial 8078   exenatide other dosesinsulin glargine (add on MET/SU) -
LEAD 6 (Buse) exe vs lira, 2009     exenatide 10µg twice dailyliraglutide 1.8mg -
DURATION-2 (Bergenstal) (vs pioglitazone), 2010      NCTexenatide weeklypioglitazoneLow risk of bias suggesting-100%
DeFronzo (EXE vs ROSI), 2010     exenatide 20µg/drosiglitazone add on METExploratory negative
DURATION-2 (Bergenstal) (vs sitagliptin), 2010      NCTexenatide weeklysitagliptinLow risk of bias suggesting-100%
DeFronzo, 2008      NCTexenatide 20µg/dsitagliptin (add on MET)Low risk of bias -
Drucker, 2008      NCTexenatide 20µg/dweekly exenatide -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons